Early Access — free while we kick the tires
EdgarHawk

McCulloch Kevin

See Remarks

Officer
1 filing analyzed · 1 company · Latest 2025-06-16

Companies

Company Buys Sells Direction
Xeris Biopharma Holdings, Inc. XERS 1 0 Net buying

Activity

June 2025
medium
Buy
25,000 shares
$109,475
Significance 4/10

CFO Kevin McCulloch bought 25,000 XERS shares at $4.38; stock -25.0% from 52-week high, company posting losses.

Kevin McCulloch purchased 25,000 shares at $4.38 on 2025-06-13, increasing his holdings from 1,683,585 shares to 1,708,585 shares (a 1.5% increase). The transaction occurs against a backdrop of significant price pressure: the stock has declined 9.8% over the last 30 days, 15.7% over 90 days, and is now 25.0% below its 52-week high of $5.87. Despite positive revenue growth of 23.9% year-over-year and recent quarterly revenue of $60.1M, the company remains unprofitable with a full-year net loss and most recent quarterly loss of $9.2M. This purchase by a senior executive adds to his substantial existing position but occurs when the stock is materially off recent highs and the company is not yet cash-flow positive.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access